• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Reunion Neuroscience Inc.

    8/1/23 9:50:54 AM ET
    $REUN
    Medical/Nursing Services
    Health Care
    Get the next $REUN alert in real time by email
    S-8 POS 1 tm2322320d1_s8pos.htm S-8 POS

    As filed with the Securities and Exchange Commission on August 1, 2023

     

    Registration No. 333-268481

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-8
     
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
    Reunion Neuroscience Inc.
    (Exact Name of Registrant as Specified in its Charter)
     

    Canada

     

    Not Applicable

    (State or other Jurisdiction
    of Incorporation or Organization)
      (I.R.S. Employer Identification No.)
         
    30 Duncan Street, Lower North Suite    

    Toronto, ON, Canada

     

    M5V 2C3

    (Address of Principal Executive Offices)   (Zip Code)
     
    EQUITY COMPENSATION PLAN
    (Full titles of the plan)
     
    Curtis Weber
    Reunion Neuroscience Inc.
    30 Duncan Street, Suite 401
    Toronto, Ontario
    Canada, M5V 2C3
    Tel: (833) 222-0084
    (Name, address, including zip code, and telephone number,
    including area code, of agent for service)
       
    Steve M. Cohen, Esq.
    Morgan, Lewis & Bockius LLP
    502 Carnegie Center
    Princeton, New Jersey
    (609) 919-6600
    (With copies to)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨ Accelerated filer   ¨ Non-accelerated filer   x Smaller reporting company   ¨ Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE REGARDING DEREGISTRATION

     

    This post-effective amendment relates to Registration Statement No. 333-268481 filed on November 18, 2022 (the “Registration Statement”) by Reunion Neuroscience Inc. (the “Registrant”) with the Securities and Exchange Commission (the “SEC”) pertaining to the offering by the Registrant of 1,746,777 common shares of the Registrant (the “Shares”), pursuant to option awards, restricted share units, performance share units and/or dividend share units issuable under the Registrant’s Equity Compensation Plan.

     

    On August 1, 2023, as a result of the completion of the transactions contemplated by the Arrangement Agreement, dated as of May 31, 2023, by and among the Registrant, 20231089 Parent, Inc. (the “Parent”), and the Parent’s wholly owned subsidiary, the Registrant was acquired by Parent. In connection therewith, on August 1, 2023, the Nasdaq Global Select Market filed a Form 25-NSE to report the delisting of the Shares from the Nasdaq Global Select Market and to deregister the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Registrant intends to file a Form 15 with the SEC, requesting suspension of reporting obligations under Section 13 and 15(d) of the Exchange Act following the date hereof.

     

    In connection with the foregoing, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking contained in the Registration Statement to remove from registration by means of this post-effective amendment any of the securities registered under the Registration Statement that remain unsold at the termination of the offering, the Registrant hereby removes from registration all of its securities registered but unsold under the Registration Statement as at the date hereof.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this post-effective amendment on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Toronto, Ontario on August 1, 2023.

     

        REUNION NEUROSCIENCE INC.
        (Registrant)
           
        By /s/ Gregory Mayes
        Gregory Mayes
        President and Chief Executive Officer

     

    No other person is required to sign this post-effective amendment to the registration statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

     

     

    Get the next $REUN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REUN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $REUN
    Leadership Updates

    Live Leadership Updates

    See more
    • Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

      - Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed psychiatrist Fred Grossman, D.O., FAPA, to its Board of Directors. Dr. Grossman has over two decades of experience in clinical development and medical affairs, ph

      4/3/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

      TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Pursuant to the terms and conditions of a definitive arrangement agr

      8/1/23 9:03:29 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

      TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to announce that, earlier today, the Ontario Superior Court of Justice (Commercial List) granted a final order approving the proposed arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, with affiliates of MPM BioImpact ("MPM"). As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2

      7/14/23 4:05:00 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

      TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to announce the voting results of the special meeting of shareholders of Reunion held yesterday, July 12, 2023 (the "Meeting"). At the Meeting, shareholders voted in favour of a special resolution (the "Arrangement Resolution") to approve the proposed plan of arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, whereby affiliates of MPM BioImpact would acquire Reu

      7/13/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Reunion Neuroscience Inc.

      15-12G - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/18/23 12:56:55 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form 6-K filed by Reunion Neuroscience Inc.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/1/23 10:54:08 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form F-10POS filed by Reunion Neuroscience Inc.

      F-10POS - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/1/23 9:53:09 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)

      SC 13D/A - Reunion Neuroscience Inc. (0001865482) (Subject)

      8/1/23 10:53:55 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by Reunion Neuroscience Inc.

      SC 13G - Reunion Neuroscience Inc. (0001865482) (Subject)

      6/20/23 4:06:16 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13D filed by Reunion Neuroscience Inc.

      SC 13D - Reunion Neuroscience Inc. (0001865482) (Subject)

      6/12/23 5:30:28 PM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Financials

    Live finance-specific insights

    See more
    • Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

      Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022, Reunion Held CAD $32.4 Million in Cash and Cash Equivalents TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today provided a business update and re

      2/14/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

      TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion's fiscal 2023 third quarter ended December 31, 2022, before market open on Tuesday, February 14, 2023. The Company will hold a conference call and webcast to discuss its results at 8:30 a.m. ET the same day. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conferen

      2/2/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care